I thought this was interesting. Periodontal disease would probably be a good market and another target that would keep Apabetalone relevant while management tries to figure out their collective job. Maybe not a glory market for a big hitter like Don, who keeps striking out as he swings for the fences, but probably an application that would be inexpensive to investigate. Who know perhaps try a little actual business development and find a partner. The drug has already proven to be safe and I thought the comparison to JQ-1 was interesting from a real world potential use perspective.

https://www.researchgate.net/publication/374862106_Selective_BET_inhibitor_RVX_-208_ameliorates_periodontal_inflammation_and_bone_loss